2023
Examining racial differences in smoking outcomes among smokers enrolled in an intravenous nicotine infusion study
Schwartz E, Palmisano A, Gueorguieva R, DeVito E, Sofuoglu M. Examining racial differences in smoking outcomes among smokers enrolled in an intravenous nicotine infusion study. Addictive Behaviors 2023, 140: 107615. PMID: 36640662, PMCID: PMC9911383, DOI: 10.1016/j.addbeh.2023.107615.Peer-Reviewed Original ResearchConceptsSmoking-related illnessesNegative drug effectsNicotine clearanceOvernight abstinenceNicotine infusionDrug effectsMentholated cigarettesWhite individualsBlack individualsAcute pharmacologic effectsSmoking-related morbiditySmoking-related diseasesAdministration of nicotineSmoking-related outcomesSubjective drug effectsShort-term abstinenceLower ratesTrend level differenceLarge racial disparitiesNicotine administrationNicotine dosesTrend-level significancePharmacologic effectsTreatment strategiesOutcome measures
2019
Targeting neuroinflammation with minocycline in heavy drinkers
Petrakis IL, Ralevski E, Gueorguieva R, Sloan ME, Devine L, Yoon G, Arias AJ, Sofuoglu M. Targeting neuroinflammation with minocycline in heavy drinkers. Psychopharmacology 2019, 236: 3013-3021. PMID: 30919006, PMCID: PMC6764907, DOI: 10.1007/s00213-019-05205-3.Peer-Reviewed Original ResearchConceptsPro-inflammatory cytokine releaseEthanol-induced inflammationMicroglial activationCytokine levelsCytokine releaseHeavy drinkersSecond-generation tetracycline antibioticDose of minocyclinePlacebo-controlled trialSerum cytokine levelsSubjective responsesBaseline cytokine levelsEffects of minocyclineViable treatment strategyShort-term treatmentAlcohol use disorderNeuroimmune modulationMinocycline treatmentNeuroimmune signalingMinocycline effectsIntravenous ethanolEthanol intakeSedative responseTreatment strategiesPreclinical studies
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply